RAD51 and cancer: Blocking GRB2 activity may therefore offer a biological and potentially attractive clinical alternative to stabilizing RAD51 filaments by inhibiting the PolQ ATPase stimulation by ssDNA by novobiocin, which has entered cancer clinical trials66.